Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir/Abacavir/Lamivudine in Antiretroviral-Naive Adults (SYMTRI): A Multicenter Randomized Open-Label Study (PReEC/RIS-57)

BACKGROUND: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) is the reference for combination therapy based on protease inhibitors due to its efficacy, tolerability, and convenience. Head-to-head randomized comparisons between D/C/F/TAF and combination therapy based on integrase...

Descripción completa

Detalles Bibliográficos
Autores principales: Podzamczer, D, Micán, R, Tiraboschi, J, Portilla, J, Domingo, P, Llibre, J M, Ribera, E, Vivancos, M J, Morano, L, Masiá, M, Gómez, C, Fanjul, F, Payeras, A, Inciarte, A, Estrada, V, Rivero, A, Castro, Á, Bernal, E, Vinuesa, D, Knobel, H, Troya, J, Macías, J, Montero, M, Sanz, J, Navarro-Alcaraz, A, Caicedo, A, Fernández, G, Martínez, E, Moreno, S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Major Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883591/
https://www.ncbi.nlm.nih.gov/pubmed/35237700
http://dx.doi.org/10.1093/ofid/ofab595

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883591/
https://www.ncbi.nlm.nih.gov/pubmed/35237700
http://dx.doi.org/10.1093/ofid/ofab595

Ejemplares similares